3 ms·

> So says the cardiology fellow… Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? > One theory as to

> So says the cardiology fellow… Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? > One theory as to why statins have a small degree of influence is that they actually have an anti-inflammatory action. When my father talks with his patients, he finds many of them couldn't tolerate statins' side effects. Given the predictable effects of LDL-cholesterol lowering on MACE and death, invoking beneficial mechanisms of statins beyond LDL-cholesterol lowering (e.g., by anti-inflammatory effects) is not that well supported (or necessary to explain the benefits), but it's not out of the realm of possibility.

tcj_phx 10y ago
> Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? The American Heart Association still promotes Ancel Keys' dietary philosophy, so everything they touch is tainted. An appology for The Mistake (promoting vegetable oil) is necessary to begin the process of rebuilding trust. I subscribe to a medical news email - one of the recent editorials was about needing to re-examine the profession's obsession with cholesterol. When I find the link I'll post again. But basically the gist is that the CETP agents are good at lowering cholesterol levels, but not so good at lowering mortality, so maybe the hypothesis needs to be reconsidered.
- carbocation 10y ago
  Apheresis, HMG-CoA reductase inhibition (statins), PCSK9 inhibition (-cumabs), and NPC1L1 inhibition (ezetimibe) all lead to reduced LDL-C. Statins and ezetimibe lead to reduced MACE and death. The -cumabs should be reporting trial results in the next 12 months, but the genetic data strongly suggests that they will reduce mortality. Unusual for cholesterol modification agents, some of the CETP drugs (which were designed around their HDL-C raising properties but do lower LDL-C) increased MACE, while others had neutral effect, so there is something about CETP that we have yet to understand.
  - tcj_phx 10y ago
    I can't match you on credentials or acronyms, but I'm pretty good at figuring out what matters for improving my own health. "Should cardiologists evaluate their obsession with LDLs and HDLs?" - http://www.kevinmd.com/blog/2016/04/should-cardiologists-evaluate-their-obsession-with-ldls-and-hdls.html?pop=0&ba=1 http://www.kevinmd.com/blog/2016/04/should-cardiologists-eva... (April 2016) Saw this link on the sidebar: "Slow Medicine: Pressing Pause on Statins For Primary Prevention" - http://www.medpagetoday.com/Blogs/SlowMedicine/61836 http://www.medpagetoday.com/Blogs/SlowMedicine/61836 (December 4 2016) I would estimate that the cholesterol fetish has about 2 more years before it begins to slide into irrelevance, and the field begins to refocus on the causes behind the symptom. A classic fun movie clip: https://www.youtube.com/watch?v=02Or-Hx3yqc https://www.youtube.com/watch?v=02Or-Hx3yqc
coldtea 10y ago
>Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? If there were differing opinions and results on some computer science subjects by different specialties (cryptography, data science, language design, algorithms, etc), then yes.

tcj_phx 10y ago

> Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? The American Heart Association still promotes Ancel Keys' dietary philosophy, so everything they touch is tainted. An appology for The Mistake (promoting vegetable oil) is necessary to begin the process of rebuilding trust. I subscribe to a medical news email - one of the recent editorials was about needing to re-examine the profession's obsession with cholesterol. When I find the link I'll post again. But basically the gist is that the CETP agents are good at lowering cholesterol levels, but not so good at lowering mortality, so maybe the hypothesis needs to be reconsidered.

carbocation 10y ago
Apheresis, HMG-CoA reductase inhibition (statins), PCSK9 inhibition (-cumabs), and NPC1L1 inhibition (ezetimibe) all lead to reduced LDL-C. Statins and ezetimibe lead to reduced MACE and death. The -cumabs should be reporting trial results in the next 12 months, but the genetic data strongly suggests that they will reduce mortality. Unusual for cholesterol modification agents, some of the CETP drugs (which were designed around their HDL-C raising properties but do lower LDL-C) increased MACE, while others had neutral effect, so there is something about CETP that we have yet to understand.
- tcj_phx 10y ago
  I can't match you on credentials or acronyms, but I'm pretty good at figuring out what matters for improving my own health. "Should cardiologists evaluate their obsession with LDLs and HDLs?" - http://www.kevinmd.com/blog/2016/04/should-cardiologists-evaluate-their-obsession-with-ldls-and-hdls.html?pop=0&ba=1 http://www.kevinmd.com/blog/2016/04/should-cardiologists-eva... (April 2016) Saw this link on the sidebar: "Slow Medicine: Pressing Pause on Statins For Primary Prevention" - http://www.medpagetoday.com/Blogs/SlowMedicine/61836 http://www.medpagetoday.com/Blogs/SlowMedicine/61836 (December 4 2016) I would estimate that the cholesterol fetish has about 2 more years before it begins to slide into irrelevance, and the field begins to refocus on the causes behind the symptom. A classic fun movie clip: https://www.youtube.com/watch?v=02Or-Hx3yqc https://www.youtube.com/watch?v=02Or-Hx3yqc

coldtea 10y ago

>Would you say "so says the cryptographer" to circumscribe something that `tptacek says about cryptography? If there were differing opinions and results on some computer science subjects by different specialties (cryptography, data science, language design, algorithms, etc), then yes.